Patient-derived colorectal cancer stem cells (CR-CSCs) were first isolated on the basis of CD133 expression and proved to induce tumors in mice that resembled the original malignancy [17], thus representing a reliable pre-clinical model. This evidence concerns the gene PROM1 and colorectal cancer.